Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled phase 2 trial of GSK573719 in COPD
2009-016690-15Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of umeclidinium in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoint: Change from baseline in trough FEV1 at Day 29. Started Nov 2009; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-016690-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016690-15.